Skip to content

Master Allergen Child Nutrition. Reintroduction of Small Doses

Reintroduction of Small Doses of Food in Allergic Children to Lightening the Elimination Diet.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02384707
Acronym
MANOE
Enrollment
400
Registered
2015-03-10
Start date
2011-05-31
Completion date
2015-12-31
Last updated
2015-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Food Allergies

Brief summary

Reintroduction of small doses of food in allergic children to lightening the elimination diet.

Detailed description

In four groups of allergic children (peanuts, wheat , milk and egg), a reintroduction of 4 small increasing doses of allergen is carried out progressively double-blind placebo- cons , randomized, during a hospitalization. The procedure for reintroduction of small doses (MPD) is stopped at the appearance of intolerance (in taking a dose of allergen or placebo) defined by the onset of allergic symptoms or objective severe abdominal pain within 45 minutes of taking.

Interventions

OTHERallegic food

Reintroduction procedure for small doses : * Administration of the first dose * Clinical monitoring for 45 minutes * Administration of the second dose

OTHERPlacebo

Sponsors

University Hospital, Angers
Lead SponsorOTHER_GOV

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
9 Months to 16 Years
Healthy volunteers
No

Inclusion criteria

* Allergic children 1 and 16 years for peanut, egg and wheat. So, for milk between 9 months and 16 years. * Accurate diagnostic * Allergic react rapidly and acute

Exclusion criteria

* severe disease

Design outcomes

Primary

MeasureTime frameDescription
Tolerance for each ingested dose is assessed by a clinical score45 minutesTolerance is defined by the absence of allergy symptoms within 45 minutes of ingestion of the allergen dose in the absence of intolerance to previous placebo

Countries

France

Contacts

Primary ContactMartine Drouet
madrouet@chu-angers.fr

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026